Mechanisms of Resistance to PSMA Radioligand Therapy: Radiation Resistance Versus Dose
University of California, San Francisco
Summary
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Description
PRIMARY OBJECTIVES: I. To determine the relationship between whole body tumor absorbed dose and response Lutetium based prostate-specific membrane antigen-targeted radioligand therapy (177Lu-PSMA-RLT). II. To determine the relationship between Post-Operative Radiation Therapy Outcomes Score (PORTOS) score and response to 177Lu-PSMA-RLT. III. To determine the relative importance of radiation dose (whole body tumor absorbed dose) and radiation sensitivity (PORTOS score) as a marker of response to 177Lu-PSMA-RLT. EXPLORATORY OBJECTIVES: I. To develop novel signature of radiation sensitivity.…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Initiating treatment with Lutetium based PSMA-targeted RLT. 2. Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards. 3. Patients on warfarin, aspirin, or other anti-coagulants are e…
Interventions
- ProcedureSingle-photon emission computed tomography
Imaging procedure
- ProcedureBlood Draw
Blood draw for future research tests (45-60 mL).
- ProcedureTumor Biopsy
Guided biopsy of lesion
Locations (3)
- University of California, Los AngelesLos Angeles, California
- University of California, San FranciscoSan Francisco, California
- Memorial Sloan KetteringNew York, New York